Alector Inc. (NASDAQ: ALEC) has experienced dramatic growth in recent days, with its share price skyrocketing by 90%.
This article tells you all of the key things you need to know before you invest in Alector stock. We go through what the company is, what it does, why it is surging in value, and what our ALEC price forecast is for the next 12 months.
For those of you who want to go right ahead and purchase shares immediately, check out the section below. We have listed the two best places to buy, sell and trade Alector shares in the UK and elsewhere.
Where to buy Alector stock online today
If you want to buy or trade Alector stock, your best bet is to sign up to a reliable stockbroker. These are free or low-fee platforms that allow retail investors like yourself to build a comprehensive, de-risked investment portfolio compiled of various different assets.
Here are the two best platforms to buy ALEC stock right now:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Alector?
It is a clinical stage biopharmaceutical company. Alector’s main focus is on developing therapies for the treatment of neurodegenerative diseases.
It has a wide range of products that are currently at varying stages in the official testing process, and they could eventually form effective treatments for dementia, Azheimer’s, Parkinson’s and amyotrophic lateral sclerosis diseases.
While the biotechnology company is expected to post a quarterly loss of $0.68 per share in its upcoming report, the market has been excited by its formal collaboration deal with major pharma powerhouse GlaxoSmithKline. Together, the companies will jointly co-develop/commercialize its two monoclonal antibodies – AL001 and AL101.
Should I buy Alector shares right now?
If you want to invest in a high-risk, high-reward company that has the potential to return exponential value to shareholders, Alector stock could be a good buy.
However, be wary of the risks that come with investing in a biopharma company. Since every treatment must go through a rigorous testing process before receiving approval from the regulators, there is every chance that promising products may never achieve commercialisation.
While the emergence of GlaxoSmithKline in this story helps quash some of these fears, there is no getting away from the fact that much of Alector’s potential success hinges on unpredictable factors.
Alector price target
After its recent dramatic growth, our revised ALEC price prediction is as follows: a 12-month high of $55, a median of $37 and a low of $29.